BIOVF (Swedish Orphan Biovitrum AB) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 05, 2026)


BIOVF Swedish Orphan Biovitrum AB BIOVF
83 GF Score
Price $48.00
GF Value $34.48
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2026-07-05), Swedish Orphan Biovitrum AB's Predictability Rank is 2.5-Stars. Swedish Orphan Biovitrum AB's intrinsic value calculated from the Discounted Dividend model is $73.62 and current share price is $48.00. Consequently,

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

BIOVF vs ZTS, UTHR: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) falls into.


BIOVF
83GF Score
Swedish Orphan Biovitrum AB BIOVF
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Margin of Safety % (DCF Dividends Based) Calculation

Swedish Orphan Biovitrum AB's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)=(Intrinsic Value: DCF (Dividends Based)-Current Price)/Intrinsic Value: DCF (Dividends Based)
=(0.00-48.00)/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $48.00 is trading 39.2% above its estimated GF Value™ of $34.48. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for BIOVF:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $34.48 vs. price of $48.00 (39.2% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score

Get the complete analysis for BIOVF

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$48.00
Price
$34.48
GF Value